Scientific Advisory Board

Dr. Ali Harandi has a long-standing interest and experience in mucosal immunity and adjuvants with special emphasis on vaccine and adjuvant development to counter genital herpes. Dr. Harandi and his colleagues recently developed the novel potent adjuvant CTB-CpG with combined properties of TLR9 agonist and CTB. Dr. Harandi has coordinated several collaborative research projects on mucosal adjuvants and vaccines against genital herpes, involving the Karolinska Institute, Lund University, Linköpings University, WHO collaborating Institute of Primate Research in Nairobi, a Plant-based vaccine Center in Giza Egypt and Finlay Institute in Cuba, and is currently involved in a FP7 funded project on multivalent nanoparticle-based vaccines for HIV and genital herpes.

Dr. Harandi has been serving as expert, advisor and member to a number of national and European committees including the European Commission (EC)-DG Research Health, European Developing Countries Clinical Trial Partnership (EDCTP) as well as advisor to several EC funded consortia and European biotech companies. Dr. Harandi has organized several international workshops and symposia on vaccines and adjuvants and has given several keynote and invited talks in international meetings and conferences.

Dr Brian Angus is the Director of the Wellcome Trust UK Centre for Clinical Tropical Medicine in Oxford. Dr Angus joined the Nuffield Department of Clinical Medicine in 1993. He originally worked in Thailand and Ghana studying pharmacokinetics in severe malaria and melioidosis. His research focus is now on clinical trials in HIV, Chronic Fatigue Syndrome, Clostridium difficile associated diarrhoea and new vaccines. Dr. Angus is Clinical Tutor in Medicine and Reader in Infectious Diseases at the University of Oxford and honorary Senior Clinical Scientist at the MRC HIV CTU.

Sunil Shaunak, M.D Ph.D. serves as Professor of Infectious Diseases at the Hammersmith Hospital, Imperial College London. Prof. Shaunak Co-Founded PolyTherics Ltd. in 2002 and serves as its Chairman of the Scientific Advisory Board. Prof. Shaunak was awarded the prestigious Research Breakthrough Award for the development of a novel medication for hepatitis C by Hammersmith Hospital NHS Trust.

OVERVIEW

CDVAX is a project funded under the European Union 7th Framework. The aim of CDVAX is to take forward a novel and highly innovative vaccine that could provide protection to Clostridium difficile infection. The project will evaluate vaccines in a human clinical trial.

To learn more about Clostridium difficile and the illness it causes click here.